Group 1 - The Hong Kong stock market experienced a comprehensive rebound, with the pharmaceutical sector continuing its recovery trend, led by Innovent Biologics, which secured an $8.85 billion business development deal, resulting in a daily increase of 7.42% [1][3] - Other leading stocks such as BeiGene, CSPC Pharmaceutical Group, and 3SBio also saw gains, contributing to the overall positive sentiment in the market [1] - The Hong Kong Stock Connect Innovation Drug ETF (520880) opened high and rose by 1.77%, successfully maintaining an upward trend and surpassing the 10-day moving average, with a total transaction volume of 381 million yuan [1] Group 2 - On February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3] - The total transaction scale for licensing out innovative drugs in China is expected to reach a record $135.7 billion by 2025, with significant collaborations emerging in early 2026, validating the global value of domestic innovative drug pipelines [3] - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," with a focus on commercial realization, indicating a favorable long-term outlook for quality stocks in the sector [3] Group 3 - The Hong Kong medical device sector is characterized by strong innovation, with several companies showing improved operational performance and attractive investment value due to low valuations [5] - Companies like Mindray and Kefu Medical are expected to go public in Hong Kong this year, potentially increasing investment opportunities within the medical device sector [5] - The recommendation is to invest in the Hong Kong Stock Connect Innovation Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137), which focus on innovative drug development and encompass various hot concepts such as AI healthcare and internet pharmacies [5]

Group 1 - The Hong Kong stock market experienced a comprehensive rebound on February 9, with the pharmaceutical sector continuing its recovery trend, led by Innovent Biologics, which secured an $8.85 billion BD deal, resulting in a peak increase of 8.55% and a closing rise of 7.42% [1][3] - Other leading stocks such as BeiGene rose over 3%, while CSPC Pharmaceutical, China Biologic Products, and 3SBio also saw collective gains [1][3] - The Hong Kong Stock Connect Innovation Drug ETF (520880) opened high, reaching an increase of 2.75% and closing up 1.77%, successfully maintaining an upward trend and surpassing the 10-day moving average with a total transaction volume of 381 million yuan [1][3] Group 2 - On the evening of February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3] - The total transaction scale for China's innovative drug License-out is expected to reach a record $135.7 billion by 2025, with significant collaborations emerging in 2026, including major deals involving CSPC and AstraZeneca ($18.5 billion) and Rongchang and AbbVie ($5.6 billion), validating the global value of domestic innovative drug pipelines [3] - According to Open Source Securities, the Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," entering a commercialization harvest period, with many quality targets showing significant valuation attractiveness after nearly two quarters of correction [3] Group 3 - The Hong Kong Stock Connect medical sector showed active performance, particularly in AI medical and brain-computer interface concept stocks, with major players like JD Health, Alibaba Health, and Ping An Good Doctor all rising around 3% [3] - The AI medical sector is rapidly penetrating the consumer end, expanding application scenarios from smart consultations to chronic disease management, leading to a revaluation of internet medical platforms like Alibaba Health and JD Health [3] Group 4 - CITIC Securities noted that the overall innovation attribute of the Hong Kong medical device sector is strong, with some companies' innovative products having potential for license-out or acquisition [5] - The fundamentals of most companies in the industry are continuously improving, highlighting the investment value of low valuations [5] - It is anticipated that Mindray Medical and Caresyntax will be listed in Hong Kong this year, potentially increasing investment opportunities in the Hong Kong medical device sector [5]

Market Overview - On February 9, the Shanghai Composite Index rose by 1.41%, the CSI 300 increased by 1.63%, the STAR 50 climbed by 2.51%, the CSI 1000 went up by 2.26%, the ChiNext Index surged by 2.98%, and the Hang Seng Index gained 1.76% [4] - The best-performing sectors on February 9 were telecommunications (+5.17%), comprehensive (+4.7%), media (+3.5%), electronics (+2.97%), and computers (+2.88%) [4] - The total trading volume for the A-share market on February 9 was 22,702 billion, with net outflow of southbound funds amounting to 1.887 billion HKD [4] Non-Bank Financial Sector - On February 6, the central bank and eight other departments jointly issued a notice to further prevent and manage risks related to virtual currencies [5] - The regulatory framework for Real World Assets (RWA) was officially defined for the first time, providing clear guidelines for domestic enterprises to issue asset-backed securities tokens overseas [5] - Investment opportunities include the facilitation of RWA as a financing method for the real economy, enhancing Hong Kong's position as a global digital asset center [5] - Catalysts for growth include ongoing advancements in Hong Kong's digital asset policies, improvements in global liquidity, and a rebound in market sentiment [5] Media Sector - The media sector experienced a weekly decline of 3.24% from February 2 to February 6, primarily influenced by the downturn in US AI large model discussions [7] - Notable performers included Hengdian Film City (+30.98%), Happiness Blue Sea (+7.45%), and Bona Film Group (+7.40%), with Perfect World’s "The Other Side" exceeding expectations [7] - Investment opportunities focus on companies involved in AI applications and media, including Kunlun Wanwei, Huanrui Century, and Tencent-related firms [7] - Catalysts include significant updates in domestic AI applications and the scheduled release of Perfect World’s "The Other Side" [7] Computer Sector - The domestic policy and industry window for brain-computer interfaces are aligning, with a significant increase in clinical case numbers [9] - Brain-computer interfaces are expected to become a preferred method for human-machine communication, reaching a broader market [9] - Investment opportunities are concentrated among companies developing non-invasive technologies and those in the rehabilitation and consumer-grade brain-computer product sectors [9] - Catalysts include the anticipated mass production of Neuralink's first product, Telepathy [9]

Group 1 - The company, Aopu Technology (603551), focuses its external investments on areas related to its main business [1] - The company explicitly stated that it does not engage in investments related to robotics vision, energy storage, brain-computer interfaces, photovoltaics, or semiconductors [1] - Specific business information should be referred to in the company's official disclosures [1]

Core Viewpoint - The company, specializing in the IVD (in vitro diagnostics) sector, is under investigation by the China Securities Regulatory Commission (CSRC) for alleged misleading disclosures related to a strategic cooperation agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [2][7] Company Overview - The company is engaged in the research, production, sales, and service of IVD products and is recognized as a national high-tech enterprise with numerous intellectual property rights [6][7] - It has received multiple awards, including the Shenzhen Science and Technology Progress Award and the Guangdong Province Patent Award [6] Regulatory Issues - On February 6, 2026, the CSRC issued a notice of investigation due to potential violations of information disclosure laws concerning the strategic cooperation agreement with Brain Machine Star Chain [2][7] - The initial announcement on January 6, 2026, claimed collaboration in product development and market promotion, but subsequent disclosures clarified that the products were still in early research or preclinical stages [2][7] Market Reaction - The "brain-machine interface" concept is currently a market hotspot, leading to a significant increase in the company's stock price, which rose by 6.52% with trading volume up by 299% compared to the previous day [3][8] - The company is urged to ensure that all disclosures related to this hot topic are accurate and complete to avoid misleading investors [3][8]

Core Viewpoint - Two listed companies, Yahui Long and Tiansheng New Materials, were investigated for information disclosure violations, impacting their stock prices and investor confidence [1][3]. Group 1: Investigation Reasons - Yahui Long's investigation is linked to misleading statements in a recent announcement regarding a strategic cooperation in the "brain-computer interface" sector, which led to a significant stock price increase before a corrective announcement was made [3][4]. - Tiansheng New Materials is under investigation for failing to disclose related party transactions, particularly concerning its financial information from 2023, with ongoing uncertainty about the specifics of the violations [4]. Group 2: Financial Performance and Challenges - Yahui Long reported a significant decline in performance, with a 7.69% drop in revenue to 1.287 billion yuan and a 72.36% decrease in net profit to 60.42 million yuan for the first three quarters of 2025, attributing the downturn to healthcare cost control policies and increased market competition [6][7]. - Tiansheng New Materials faces a more severe situation, with a 16.71% drop in revenue to 334 million yuan and a net loss of 83.12 million yuan for the same period, alongside a negative equity of 30.62 million yuan, risking delisting if the situation does not improve [7]. Group 3: Regulatory Environment - The recent investigations of Yahui Long and Tiansheng New Materials are part of a broader trend, with eight companies being investigated by the regulatory authority since the beginning of 2026, indicating a tightening regulatory environment with a focus on specific disclosure violations [9].

Group 1 - The core focus of the meeting between Jiangsu Brain-Computer Interface Research Institute and SuShang Bank is to explore the investment and loan linkage model for the brain-computer interface industry, aiming to empower innovation and development in this sector [1][5] - Jiangsu Brain-Computer Interface Research Institute, established on September 28, 2025, has gathered 15 core member units, creating a collaborative innovation network that integrates government, industry, academia, research, and medical sectors [3] - Brain-computer interface technology establishes real-time communication and control systems between the human brain and external devices, representing a critical area in national technological competition and is included in China's "14th Five-Year Plan" as one of the six future industries [3] Group 2 - SuShang Bank has made significant progress in digital banking and inclusive financial services, with AI models deeply applied in credit approval and other core business modules [4] - The bank has supported over 4,000 high-tech, specialized, and unicorn enterprises with a total loan amount exceeding 80 billion yuan, focusing on the needs of startup technology companies [4] - The Vice President of Jiangsu Brain-Computer Interface Research Institute praised SuShang Bank's digital development and expressed willingness to collaborate in promoting the high-quality development of the brain-computer interface industry in Jiangsu [5]

Group 1: Innovation in Medical Technology - Innovation Medical (002173) has established itself in the medical service sector, focusing on brain-computer interface (BCI) technology for clinical applications, particularly in neuro-rehabilitation and cardiovascular treatment [1][20] - The company's BCI-4000 product is in Phase III clinical trials, utilizing invasive electrodes to collect brain signals for device control, aiding rehabilitation for high-level paraplegics [1][20] - With the implementation of insurance reimbursement policies for BCI, the clinical transition process is expected to accelerate, potentially leading to significant growth in the neuro-rehabilitation business [1][20] Group 2: Digital Entertainment and AI Integration - Talking Tom (300459) leverages its popular IPs in digital entertainment and is actively exploring the integration of AI with brain-computer interfaces to create immersive interactive experiences [2][21] - The core business includes IP operation, mobile app development, and digital content creation, focusing on leisure and children's education [2][21] - The company aims to develop brain-controlled games and immersive entertainment applications, enhancing user engagement and monetization capabilities [2][21] Group 3: Precision Components in Medical Devices - Meihua Medical (301363) specializes in manufacturing precision medical components, providing essential support to global medical device companies, and has recently entered the brain-computer interface supply chain [3][22] - The company produces components for cardiovascular and neuro-interventional devices, including precision structural parts for BCI equipment [3][22] - As demand for BCI devices increases, the company anticipates a steady growth in orders for precision components, enhancing collaboration with BCI firms [3][22] Group 4: AI and Brain-Computer Interface Algorithms - Yanshan Technology (002195) focuses on brain-like intelligence and AI, with a strong emphasis on developing neural signal decoding algorithms for brain-computer interfaces [4][23] - The company aims to optimize brain signal decoding efficiency through AI algorithms, enhancing the precision control capabilities of BCI devices [4][23] - As the demand for algorithm precision in BCI increases, the company expects growth in algorithm licensing and system integration services [4][23] Group 5: Network Solutions for Brain-Computer Interfaces - StarNet Ruijie (002396) is a leading provider of network equipment and solutions, exploring network support solutions for brain-computer interface applications [5][25] - The company offers high-speed data transmission and processing solutions for BCI devices, facilitating real-time brain signal transmission and cloud analysis [5][25] - With the rising demand for data transmission efficiency in BCI, the company anticipates continued growth in high-speed network equipment demand [5][25] Group 6: Pain Management and Neuroregulation - Aipeng Medical (300753) specializes in pain management and neuroregulation, exploring the application of brain-computer interfaces in postoperative pain relief and neuro-rehabilitation [6][26] - The company focuses on developing devices for pain management and neuroregulation, aiming to enhance treatment efficiency through brain-computer technology [6][26] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [6][26] Group 7: Security and Identity Verification - Entropy Technology (301330) leverages biometric recognition and identity verification technologies, applying brain-computer interfaces in security and identity authentication [7][27] - The company provides solutions for financial, governmental, and transportation sectors, focusing on the development of BCI applications for secure interactions [7][27] - As the demand for precision and security in identity verification increases, the potential for BCI applications in security will gradually be realized [7][27] Group 8: Smart Control Components and IoT Solutions - Yingqu Technology (002925) specializes in smart control components and IoT solutions, providing essential support for brain-computer interface devices [8][28] - The company serves consumer electronics and smart home sectors, offering smart control components that facilitate intelligent interaction and data collection for BCI devices [8][28] - With the rising demand for intelligent BCI devices, the company expects a continuous increase in orders for smart control components [8][28] Group 9: Precious Metal Materials for BCI Electrodes - Guiyan Platinum (600459) focuses on the research and production of precious metal materials, providing critical materials for brain-computer interface electrodes [9][29] - The company supplies platinum-based alloy materials that enhance the biocompatibility and signal stability of BCI electrodes [9][29] - As the demand for mass production of BCI electrodes increases, the company anticipates a steady growth in orders for precious metal materials [9][29] Group 10: Automotive Applications of Brain-Computer Interfaces - Yachuang Electronics (301099) is exploring the application of brain-computer interfaces in smart driving, focusing on automotive-grade chips and power semiconductors [10][30] - The company aims to implement brain control technology for vehicle operation, opening new possibilities in automotive intelligence [10][30] - As the demand for human-machine interaction in smart driving increases, the potential for BCI applications in the automotive sector will gradually be realized [10][30] Group 11: Industrial Applications of Brain-Computer Interfaces - Zhongke Information (300678) focuses on intelligent monitoring and industrial detection, applying brain-computer interfaces in industrial settings [11][31] - The company aims to utilize brain signals for equipment status monitoring and fault prediction, enhancing industrial efficiency [11][31] - As the demand for monitoring precision in industrial automation increases, the application of BCI in industrial settings is expected to accelerate [11][31] Group 12: Third-Party Testing for BCI Compliance - Puni Testing (300887) is a leading third-party testing organization, providing compliance testing services for brain-computer interface devices [12][32] - The company offers testing for biocompatibility and electromagnetic compatibility, ensuring the safety and compliance of BCI products [12][32] - As the BCI industry matures, the demand for compliance testing services is expected to grow, supporting the healthy development of the industry [12][32] Group 13: Flexible Materials for BCI Devices - Pulit (002324) specializes in the research and production of polymer materials, providing essential flexible packaging materials for brain-computer interface devices [13][33] - The company enhances the durability and biocompatibility of BCI devices through its flexible packaging solutions [13][33] - As the demand for flexible materials in BCI devices increases, the company anticipates a steady growth in orders for packaging materials [13][33] Group 14: Intelligent Equipment and Robotics - Tianqi Co., Ltd. (002009) focuses on intelligent equipment manufacturing and industrial automation, exploring the application of brain-computer interfaces in industrial robotics [14][34] - The company aims to implement brain control technology for precise robotic operation, enhancing manufacturing efficiency [14][34] - As the demand for precision in industrial automation increases, the application of BCI in robotics is expected to accelerate [14][34] Group 15: Medical Rehabilitation and Training - Chengyitong (300430) specializes in pharmaceutical intelligent manufacturing and rehabilitation equipment, exploring the application of brain-computer interfaces in rehabilitation training [15][35] - The company focuses on optimizing rehabilitation plans through brain control technology, enhancing training efficiency [15][35] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [15][35] Group 16: Military Communication and Navigation - Haige Communication (002465) is a core enterprise in military communication and navigation, providing specialized support for brain-computer interfaces [16][36] - The company offers military communication and data transmission solutions for BCI devices, enhancing interaction in specialized scenarios [16][36] - As the demand for BCI in military applications increases, the need for communication equipment is expected to grow [16][36] Group 17: Smart Terminals and Information Systems - Nanjing Panda (600775) leverages electronic manufacturing and communication technology, exploring the application of brain-computer interfaces in smart terminals [17][37] - The company aims to implement brain control technology for device operation, opening new possibilities in consumer electronics [17][37] - As the demand for interactive methods in smart terminals increases, the potential for BCI applications in consumer electronics will gradually be realized [17][37] Group 18: Biocompatible Coatings for BCI Devices - Taihe Technology (300801) specializes in fine chemicals and water treatment materials, providing essential biocompatible coating materials for brain-computer interface devices [18][38] - The company enhances the safety and durability of BCI devices through its biocompatible coatings [18][38] - As the demand for biocompatibility in BCI devices increases, the company anticipates a steady growth in orders for coating materials [18][38] Group 19: Cardiovascular and Neurointerventional Applications - Lepu Medical (300003) focuses on cardiovascular and neurointerventional fields, exploring the application of brain-computer interfaces in cardiac rehabilitation and neuroregulation [19][39] - The company aims to optimize treatment plans through brain control technology, enhancing rehabilitation efficiency [19][39] - As the demand for cardiovascular and neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [19][39] Group 20: Intelligent Nursing and Patient Monitoring - Yahua Electronics (301337) specializes in medical information systems and intelligent nursing devices, exploring the application of brain-computer interfaces in patient monitoring [20][40] - The company aims to utilize brain signals for real-time patient status monitoring, enhancing medical service efficiency [20][40] - As the demand for precise monitoring in medical services increases, the application of BCI in healthcare settings is expected to accelerate [20][40]

外交部发言人宣布： 中共中央政治局委员、外交部长王毅将于2月10日在广州出席2026年亚太经合组织（APEC）第一次高官会开 幕式并致辞。 来源：央视新闻 盘中，大幅拉升！重大突破！量子科技，突传利好！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 券中社 × 券商中国 券 中 社 扫码下载券中社APP 扫码关注券商中国公众号 quanshangcn qzs.stcn.com 舞中 券中社APP 券 商 中 国 是 证 券 市 场 权 威 媒 体 《 证 券 时 报 》 旗 下 新 媒 体 , 券 商 中 国 对 该 平 台 所 刊 载 的 原 创 内 容 享 有 著 作 权 , 未 经 授 权 禁 止 转 载 ， 否 则 将 追 究 相 应 法 律 责 任 。 百万用户都在看 央行等八部门，重磅发布！商业航天，大消息！算力，利好！脑机接口，重大突破！影响一周市场的 十大消息 利好来了！刚刚，福建重磅发布！ 重大信号！49万亿巨头，批量减持！ A股突发！多只大牛股，紧急提示风险！ 责编：汪云鹏 校对： 李凌锋 看券商中国 知天下财经 F ...

Core Viewpoint - The article discusses a breakthrough in the development of a stretchable flexible electrode for brain-machine interfaces, which addresses the challenges faced by traditional electrodes in dynamic brain environments [2][7][10]. Group 1: Technology Breakthrough - A research team led by Fang Ying has developed a stretchable flexible electrode that combines high-throughput signal acquisition with biomechanical compliance, overcoming the limitations of traditional linear electrodes [2][10]. - The new design utilizes a reconfigurable spiral array that allows the electrode to adapt to the brain's movements, significantly reducing mechanical stress on soft brain tissue [10][11]. - The electrode has been successfully tested in monkeys, achieving stable signal acquisition from 1024 channels and demonstrating long-term compatibility with brain tissue [12][14]. Group 2: Application and Validation - The electrode was implanted in a monkey's brain, allowing for the collection of over 700 cortical neuron activities, with no significant signal degradation observed after 22 weeks [14]. - The research team successfully decoded the monkey's movement intentions using the electrode, indicating its potential for assisting patients with motor function disabilities [16][17]. Group 3: Company Background and Commercialization - The technology is backed by Zhiren Medical, founded in April 2022, focusing on the development of invasive flexible brain-machine interface platforms [18][20]. - Zhiren Medical has raised over 500 million yuan in funding, with plans to advance clinical trials and establish a mass production system [20]. - The company has developed a complete system for hardware, software, decoding algorithms, and automated implantation robots, with patents granted in China and the U.S. [20]. Group 4: Industry Context and Future Prospects - The advancement aligns with the accelerating global brain-machine interface industry, with competitors like Neuralink planning large-scale production by 2026 [24]. - The Chinese government has included brain-machine interfaces in its "14th Five-Year Plan," supporting the industry's growth and development [24][25]. - The market for brain-machine interfaces in China is projected to reach 10 to 14 billion yuan by 2030, with over 200 companies currently operating in the sector [24].